Results 281 to 290 of about 253,780 (335)

Succinate Promotes M1 Polarization of Intestinal Macrophages in Mice With Necrotizing Enterocolitis Through the PI3K/AKT Pathway

open access: yesPediatric Discovery, EarlyView.
Succinate promotes macrophage to the M1 phenotype in the mouse mononuclear macrophage leukemia cells (Raw264.7 cells) and neonatal mice with NEC. Succinate activates the phosphatidylinositol 3‐kinase/protein kinase B (PI3K/AKT) pathway via succinate recepter 1 (SUCNR1), promoting M1 polarization of NEC intestinal macrophages.
Sha Liu   +6 more
wiley   +1 more source

Docosahexaenoic acid ameliorates autistic‐like behaviors by inhibiting oxidative stress and inflammatory response in neonatal maternal separation rats

open access: yesPediatric Discovery, EarlyView.
The JNK pathway and oxidative stress are activated, and pro‐inflammatory cytokines are increased in neonatal maternal separation (NMS) rats. While docosahexaenoic acid treatment suppresses the activation of JNK pathway and oxidative stress, and reduces pro‐inflammatory cytokines release, thereby improving autism‐like behavior induced by NMS.
Boqing Xu   +5 more
wiley   +1 more source

A 15‐year population‐based study on incidence and vaccination coverage in pediatric inflammatory bowel disease in Italy

open access: yesPediatric Investigation, EarlyView.
Increasing incidence of pediatric inflammatory bowel disease (IBD) and suboptimal vaccination coverage in Apulia, Italy (2009–2023). A total of 1044 incident cases of paediatric IBD were identified in the period 2009–2023 in Apulia, Italy, giving an average annual standardized incidence rate of 12.7/100 000. A significant increase in incidence occurred
Francesca Fortunato   +4 more
wiley   +1 more source

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel   +18 more
wiley   +1 more source

Onasemnogene-abeparvovec administration to premature infants with spinal muscular atrophy. [PDF]

open access: yesAnn Clin Transl Neurol
Brown SM   +7 more
europepmc   +1 more source

Reducing Iatrogenic Blood Losses in Premature Infants. [PDF]

open access: yesPediatrics
Sharma M   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy